Latest Observability News

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Southern Cross Gold Consolidated has reported exceptional high-grade gold intersections from deep drilling at its Christina prospect, confirming robust mineralization extending 350 metres below previous hits and expanding the Sunday Creek project's footprint.

Nickel Industries reveals a substantial Exploration Target of 350 to 700 million dry metric tonnes at 0.9% to 1.1% nickel for its Sampala Project, complementing an existing 187 million dmt resource. The company has initiated mine development and haul road construction, positioning itself for a secure nickel supply chain.

Barton Gold has confirmed significant high-grade silver alongside gold in its Tolmer gold system at the Tarcoola Project, prompting a new drilling campaign to explore the promising mineralisation further.

Heavy Rare Earths Limited (ASX:HRE) advanced its uranium exploration footprint in South Australia with a key asset acquisition and bolstered its balance sheet through a $2.46 million capital raise during the December 2024 quarter.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Sigma Healthcare has achieved unanimous shareholder approval for its proposed merger with Chemist Warehouse, marking a pivotal step toward reshaping Australia's pharmaceutical retail landscape. The merger now awaits final court approval, with implementation anticipated in mid-February 2025.

EUROZ HARTLEYS GROUP LIMITED has announced a fully franked ordinary dividend of AUD 0.020 per share for the six months ending December 2024, signaling steady shareholder returns.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

Astute Metals reports breakthrough lithium mineralisation at its Red Mountain Project in Nevada, with new high-grade zones and exceptional metallurgical leachability results paving the way for a maiden resource in 2025.

BCI Minerals reports robust progress in its Mardie Salt and Potash Project, achieving financial close on a $981 million debt facility and advancing construction beyond the halfway mark. The company maintains a strong focus on sustainability and safety as it targets first salt shipment in Q2 FY27.